Optimal Body Mass Index for Minimizing the Risk for Osteoporosis and Type 2 Diabetes
Overview
Affiliations
Background/aims: Body mass index (BMI) is positively associated with bone mineral density and type 2 diabetes. We investigated an optimal BMI range for osteoporosis and type 2 diabetes.
Methods: This cross-sectional study used data from the Korea National Health and Nutrition Examination Survey (KNHANES), 2008 to 2011. We included 3,774 men aged > 50 years and 4,982 postmenopausal women. Logistic regression models were applied to elucidate each BMI category's osteoporosis and diabetes risks.
Results: The prevalence of osteoporosis was 9.0% for men and 40.8% for women. The prevalence of type 2 diabetes in men was 19.7% and in women was 15.5%. In men with BMI > 25 kg/m2, the osteoporosis risk did not further increase as BMI increased. In women, BMI was linearly associated with osteoporosis risk without a plateau. In both men and women, higher BMI was associated with a higher type 2 diabetes risk. Men with a BMI of 23.0 to 24.9 kg/m2 harbored about a 30% lower osteoporosis risk than and a similar diabetes risk to those with a BMI of 21.0 to 22.9 kg/m2. In women with a BMI of 23.0 to 24.9 kg/m2, the adjusted odds ratio for osteoporosis was 0.72 (95% confidence interval, 0.59 to 0.87); the diabetes risk was not higher than in those with a BMI of 21.0 to 22.9 kg/m2.
Conclusion: For Korean men aged > 50 years and postmenopausal women, a BMI of 23.0 to 24.9 kg/m2 was the optimal range for minimizing osteoporosis and type 2 diabetes risks simultaneously.
Huang M, Xing F, Hu Y, Sun F, Zhang C, Xv Z Front Endocrinol (Lausanne). 2025; 16:1435295.
PMID: 40041284 PMC: 11876022. DOI: 10.3389/fendo.2025.1435295.
Bae J, Nelson D, Boye K, Mather K BMC Public Health. 2025; 25(1):273.
PMID: 39844122 PMC: 11756071. DOI: 10.1186/s12889-024-21061-z.
Prevalence and Risk Factors of Osteoporosis: A Cross-Sectional Study in a Tertiary Center.
Ozmen S, Kurt S, Timur H, Yavuz O, Kula H, Demir A Medicina (Kaunas). 2025; 60(12.
PMID: 39768987 PMC: 11677826. DOI: 10.3390/medicina60122109.
The influence of microbiota on the efficacy and toxicity of immunotherapy in cancer treatment.
Mahmoudian F, Gheshlagh S, Hemati M, Farhadi S, Eslami M Mol Biol Rep. 2024; 52(1):86.
PMID: 39724461 DOI: 10.1007/s11033-024-10188-2.
Zhang F, Chen Y, Wang S, Shi Z, Zhong Y, Zhu S BMJ Open. 2024; 14(8):e087142.
PMID: 39181552 PMC: 11344496. DOI: 10.1136/bmjopen-2024-087142.